Abstract
The SARS-CoV-2 pandemic has impacted public health systems all over the world. The Delta variant seems to possess enhanced transmissibility, but no clear evidence suggests it has increased virulence. Our data shows that pre-exposed individuals had similar neutralizing activity against the authentic COVID-19 strain and the Delta and Epsilon variants. After one vaccine dose, the neutralization capacity expands to all tested variants. Healthy vaccinated individuals showed a limited breadth of neutralization. One vaccine dose induced similar neutralizing antibodies against the Delta compared to the authentic strain. However, even after two doses, this capacity only expanded to the Epsilon variant.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Puerto Rico Science, Technology and Research Trust supported research reported in this work under agreement number 2020-00272 to AME and CAS. Also, the University of Puerto Rico contributed with the UPR-COVID-19 Grant to CAS and AME. This work was also supported by 1U01CA260541-01 to CAS (NCI/NIAID).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Samples used in this study were obtained from adult volunteers (>21 years old) participating in the IRB approved clinical protocol Molecular Basis and Epidemiology of Viral infections circulating in Puerto Rico, Pro0004333. Protocol was submitted to, and ethical approval was given by, Advarra IRB on April 21, 2020. Also this protocol was approved by the IRB at the Medical Sciences Campus, University of Puerto Rico.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
